Pharsight

1. List of Carnexiv drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06816054A	2015-02-06	Actavis Group PTC ehf	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9770407	December, 2014	Decision	Lundbeck Pharmaceuticals LLC
US9629797	July, 2014	Decision	James Cloyd et al

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770407	LUNDBECK PHARMS LLC	Parenteral carbamazepine formulation	Nov, 2028 (5 years from now)
US9629797	LUNDBECK PHARMS LLC	Parenteral carbamazepine formulation	Nov, 2028 (5 years from now)
US8410077	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US7635773	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9750822	LUNDBECK PHARMS LLC	Sulfoalkyl ether cyclodextrin compositions	Mar, 2029 (5 years from now)
US9493582	LUNDBECK PHARMS LLC	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (9 years from now)
US11529357	LUNDBECK PHARMS LLC	Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine	Jan, 2040 (16 years from now)

Do you want to check out CARNEXIV patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Oct 7, 2023

Market Authorisation Date: 07 October, 2016

Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Rep...

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
200MG/20ML (10MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

CARNEXIV family patents

United States

Japan

China

European Union

Australia

Korea, Republic of

Canada

Russia

Mexico

Israel

New Zealand

Spain

Hong Kong

Brazil

Denmark

Cyprus

Portugal

Poland

Slovenia

South Africa

2. List of Equetro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253	VALIDUS PHARMS	Methods for the treatment of bipolar disorder using carbamazepine	May, 2024 (11 months from now)

Do you want to check out EQUETRO patents from before 2022?

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL